StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Cost of Sales Non-GAAP Adjustments by Quarter

Cost of Sales Non-GAAP Adjustments (Intangible Amortization & Restructuring) ($M) ($M)

QuarterlyAnnual

Merck Cost of Sales Non-GAAP Adjustments: $1,251M in Q2 2026, up 68.8% from a year earlier.

Latest, Q2 2026
1,251
Period ended Jun 30, 2026
Change on a year earlier
+68.8%
741 in Q2 2025
History
38 quarters
Since Q4 2016
Sources
32
Documents cited below

Where the Q2 2026 figure comes from

“|| Cost of sales | $ | 4,395 | 1,067 | 184 | 1,251 | $ | 3,144”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 2a.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCost of Sales Non-GAAP Adjustments (Intangible Amortization & Restructuring) ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20261,251+68.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 20261,251+90.7%Form 8-K (tm2612241d1_ex99-1.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 20252,227+170.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025731-12.0%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 2025741+10.3%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025656+13.3%Form 8-K (tm2612241d1_ex99-1.htm, filed 2026-04-30) ↗
Q4 2024Dec 31, 2024822+44.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 2024831+42.1%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 2024672+34.7%Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2024Mar 31, 2024579+0.9%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 2023571+9.8%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 2023585+17.0%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 2023499-3.7%Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2023Mar 31, 2023574-20.9%Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 2022520–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 2022500+26.9%Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗

Cite this data

StockData. (2026). Merck Cost of Sales Non-GAAP Adjustments ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/nongaap-adj-cos

See every metric in the Merck KPI table. Data updated Oct 26, 2026.